Welcome to our dedicated page for Biomea Fusion news (Ticker: BMEA), a resource for investors and traders seeking the latest updates and insights on Biomea Fusion stock.
Biomea Fusion, Inc. reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on oral small-molecule therapies for diabetes, obesity and related metabolic diseases. Its updates center on icovamenib, an investigational oral covalent menin inhibitor being evaluated in type 1 and type 2 diabetes, and BMF-650, an investigational oral GLP-1 receptor agonist candidate for obesity.
Recurring announcements include COVALENT trial results and study initiations, measures of beta-cell function, C-peptide, glycemic control and safety, scientific presentations at diabetes and metabolic-disease meetings, investor-conference activity, and periodic financial results with pipeline updates.
Biomea Fusion has announced the initiation of its first-in-human (FIH) clinical trial for BMF-219, an irreversible menin inhibitor targeting relapsed or refractory acute leukemia. The FDA has cleared the Investigational New Drug application for this Phase I trial, which aims to evaluate safety and efficacy in a challenging patient population, including those with MLL/KM2TA rearrangements or NPM1 mutations. The company asserts that the aggressive nature of acute leukemia presents a significant unmet need, providing a strong rationale for its novel therapeutic approach.
Biomea Fusion (BMEA) has achieved significant milestones with its lead program, BMF-219, an irreversible menin inhibitor. The company has completed IND-enabling studies and plans to submit the IND for a Phase I/II study targeting menin-dependent acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) in the latter half of 2021. Financially, Biomea reported a net loss of $14.3 million for the first half of 2021 and increased R&D expenses of $9.0 million. As of June 30, 2021, the company holds $203 million in cash and equivalents to support ongoing initiatives.
Biomea Fusion (Nasdaq: BMEA) announced the appointment of Franco Valle as Chief Financial Officer. Valle, a seasoned financial expert, has a strong background in biotech, previously holding roles at Eidos and Iovance Biotherapeutics. He will also serve as Principal Financial Officer. CEO Tom Butler emphasized Valle's expertise in building financial systems to support growth as they prepare to submit IND for BMF-219 later this year. The company is progressing its pipeline of irreversible small molecules aimed at treating genetically defined cancers.
Biomea Fusion reported significant progress in Q1 2021, with a net loss of $5.9 million compared to $0.4 million in Q1 2020. The company raised $167 million from its IPO in April, totaling $223 million since December 2020, strengthening its financial position. Biomea is advancing its lead program, BMF-219, an irreversible menin inhibitor, aiming for an IND filing in H2 2021. Additionally, Mick Hitchcock, Ph.D., joined the Board, contributing extensive biotech experience.
Biomea Fusion, Inc. (Nasdaq: BMEA) announced the successful closing of its initial public offering, selling 9,000,000 shares at $17.00 each, generating gross proceeds of $153 million. The shares began trading on the Nasdaq Global Select Market on April 16, 2021. The underwriters also received a 30-day option to purchase an additional 1,350,000 shares. J.P. Morgan Securities, Jefferies, and Piper Sandler served as joint book-running managers for this offering, which contributes to Biomea's mission in developing treatments for genetically defined cancers.
Biomea Fusion, Inc. (Nasdaq: BMEA) has priced its initial public offering (IPO) at $17.00 per share, offering 9,000,000 shares for a total of approximately $153.0 million in gross proceeds. The IPO will begin trading on the Nasdaq Global Select Market on April 16, 2021, and is set to close on April 20, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 1,350,000 additional shares at the offering price. J.P. Morgan, Jefferies, and Piper Sandler are the joint book-running managers for the offering.